← All trials
NCT05897008
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 7, 2022
- Primary completion
- Jun 27, 2022
- Completion date
- Sep 13, 2022
- First posted
- Jun 9, 2023
- Last posted
- Jun 12, 2023
- Enrollment
- 114
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Mabtech Pharmaceutical Co., Ltd.Lead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.